An observational study in Anorexia Nervosa, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Anorexia Nervosa with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Anorexia Nervosa · Canada.
Among the 21 studies in Anorexia Nervosa with a site in Canada, this one is one of 3 that started in 2026, is one of 2 observational ones, and was the 19th registered.
471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.
Browse Anorexia Nervosa studies →7 of the 21 studies in Anorexia Nervosa with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 12–100
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
Stanford University · Sites in Canada, United States
Ages 12–18
University of California, San Diego · Sites in Canada, United States
Ages 18–55 · Women only · Healthy volunteers
University of Waterloo · Sites in Canada
Ages 17+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.
This study: 16 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 78 across 143 observational studies indexed under Anorexia Nervosa.
Median enrollment 51 across the 19 interventional studies, 55 across the 2 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 332 studies on the registry; 137 are open to participants now.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's has 1 study filed under Anorexia Nervosa — fewer than ten, so there is no comparison to draw.
5 of the studies in Anorexia Nervosa with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04174703University of WaterlooPreparing for Eating Disorders Treatment Through Compassionate Letter-Writing | 2026-12 |
| NCT07143981London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa | 2026-12-31 |
| NCT03100656University of California, San DiegoStudy of Food Aversion in Patients With Anorexia Nervosa | 2027-06-01 |
| NCT05563649Stanford UniversityConfirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa | 2027-07-31 |
| NCT06851273McMaster UniversityGuided Self Help for Eating Disorders Implementation Study | 2027-08-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies in Anorexia Nervosa with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Anorexia Nervosa (AN) is a severe, debilitating and potentially life threatening illness that is difficult to treat. A cardinal symptom of AN is the mistaken belief on the part of the individuals that they are overweight and must continue to restrict intake. This fixed false belief is a detrimental factor to recovery. It is known that AN involves disturbance in the gut microbiome (GM; the microbes that live in the lower intestinal tract). The GM also affects how one thinks and makes food choices - there appears to be a direct link between the GM and how the brain functions. This connection is thought to occur through chemical processes that convey information from the gut to the brain. It is known that fecal microbiome transplant (FMT) has been useful in treating several illnesses, including several mental illnesses. The investigators intend to deliver FMT to individuals with AN to determine the extent to which this modifies their GM, their biochemistry, their thinking processes and their moods and emotions. The investigators believe this will illuminate important aspects of AN that keep the illness in place, and that this will uncover useful approaches to better treat it.
The overall objective is to determine FMT's acceptability and the extent and means by which it helps patients with AN, restricting type. The investigators hypothesize that FMT will lead to diversification of the GM, improved metabolic and immunological status and reduced cognitive and psychiatric symptoms in patients with AN, details never investigated before. This will be due to FMT's ability to impart healthy microorganisms into the lower intestines and, thereby, improve GBM-axis signaling that may contribute to maintaining AN. The investigators propose that this will result in measurable improvement in cognitive distortions about weight, leading to reduced AN symptomatology, breaking the weight loss/AN cycle.
Specific Aims \& Hypotheses
This is a one-group, pre-/post-intervention trial of FMT in AN-restricting type, with 1-week, 3-week and 3-month follow up, administered before specialized eating disorders treatment. The hypotheses are:
This is a prospective, longitudinal, single-arm, pre-post intervention. Variables will be compared using repeated-measures analyses with each participant as their own comparator.
Participants in this study will be awaiting treatment for anorexia nervosa at London Health Sciences Centre's (LHSC, Ontario Canada) Adult Eating Disorders Service (AEDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving FMT
Feasibility of Intervention
Success will be evaluated using recruitment and retention rates, adverse event rates, and missing data rates. Scores at 75% or above will indicate high tolerability for this population that is in desperate need of additional intervention options.
Time frame: 1, 3, and 12 weeks post intervention
Shannon's Diversity Index
Metric of microbiome diversity that considers richness of number of species and abundance. Higher values indicate more diversity. A value of 0 indicates that a community only has one species.
Time frame: Pre-intervention, 12 weeks post-intervention
Activated blood cells producing Th17/Th2 cytokines
Activated blood cells producing Th17/Th2 cytokines by Luminex - IL6, IL1b, IL17, IL4, IL13 to evaluate immune responses.
Time frame: Pre-intervention, and 12-weeks post intervention
Activated blood cells producing BDNF
Activated blood cells producing BDNF measured by Enzyme-Linked Immunosorbent Assay (ELISA)
Time frame: Pre-intervention and 12-weeks post-intervention
RNA levels
RT-PCR (reverse transcription-polymerase chain reaction) for RNA levels of CCR6, CRTh2, CCR4, CXCR5 (marker genes for Th17 and Th2 cells)
Time frame: Pre-intervention and 12-weeks post-intervention
Task-switching Efficiency
-Task-switching efficiency measured using the Cued Color-Shape Switching Task, CCSST. Accuracy and response time will be computed on both single-task blocks and mixed task blocks, where participants will need to switch between colour and shape responses. Switch costs and mixing costs will be calculated from these scores.
Time frame: Pre-intervention, and 12 weeks post-intervention
Punishment sensitivity and reward sensitivity
Punishment sensitivity and reward sensitivity using the Behavioural Inhibition System/Behavioural Activation System Scales (BIS/BAS). There are three BAS scales in which higher scores equate to greater sensitivity to reward. There is one BIS scale for which higher scores equate to greater sensitivity to punishment.
Time frame: Pre-intervention and 12-weeks post-intervention
Depression
Depression evaluated using the Montgomery Asberg Depression Rating Scale (MADRS). It is a 9-item scale where higher score indicates more severe depressive symptoms.
Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention
Depression
Depression assessed with the Patient Health Questionnaire (PHQ-9), a 9-item scale evaluating the severity of depressive symptoms. Higher scores indicate more severe symptomatology.
Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention
Anxiety
Anxiety assessed using the Spielberger State/Trait Anxiety Inventory (STAI)
Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention
Anxiety
Anxiety assessed by the Generalized Anxiety Disorder 7-item scale (GAD-7)
Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention
Eating Attitudes
-Food aversion and obsessional thinking about weight using the Eating Attitudes Test (EAT-26)
Time frame: Pre-intervention, and 1-, 3-, 12-weeks post intervention
Anorexia Nervosa Symptoms
AN symptom severity with the Eating Disorders Examination Questionnaire (EDE-Q)
Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention
Plan to share: No — This is a small feasibility study. While we would not make personally identifiable information public, even the basic demographic information could be used to re-identify a participant. In light of the nature of this study we do not feel it is in the interest of our participants to share data on a repository.
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 11 months is below that.
Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →